{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:48:03Z","timestamp":1784832483889,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T00:00:00Z","timestamp":1381190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00280-013-2309-4","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T05:37:57Z","timestamp":1381124277000},"page":"1273-1282","source":"Crossref","is-referenced-by-count":16,"title":["13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients"],"prefix":"10.1007","volume":"72","author":[{"given":"Geraldo Fel\u00edcio","family":"Cunha-Junior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Bastos-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Borges","family":"Bolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Linhares","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson Antonio","family":"Pianetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Costa","family":"Cesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Gonzaga","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,8]]},"reference":[{"key":"2309_CR1","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"Meta-Analysis Group In Cancer","year":"1998","unstructured":"Meta-Analysis Group In Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537\u20133541","journal-title":"J Clin Oncol"},{"key":"2309_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N","volume":"75","author":"BN Stein","year":"1995","unstructured":"Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-Fluorouracil toxicity: analysis of a Large Scale Phase III Trial. Cancer 75:11\u201317","journal-title":"Cancer"},{"key":"2309_CR3","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB (2006) Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 12:5491\u20135495","journal-title":"Clin Cancer Res"},{"key":"2309_CR4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215\u2013237","journal-title":"Clin Pharmacokinet"},{"key":"2309_CR5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/1097-0142(19800315)45:5+<1135::AID-CNCR2820451318>3.0.CO;2-Q","volume":"45","author":"TM Woodcock","year":"1980","unstructured":"Woodcock TM, Martin DS, Damin LA, Kemeny NE, Young CW (1980) Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer 45:1135\u20131143","journal-title":"Cancer"},{"key":"2309_CR6","first-page":"2203","volume":"47","author":"GD Heggie","year":"1987","unstructured":"Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203\u20132206","journal-title":"Cancer Res"},{"key":"2309_CR7","first-page":"23","volume":"12","author":"RB Diasio","year":"1998","unstructured":"Diasio RB (1998) The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 12:23\u201327","journal-title":"Oncology"},{"key":"2309_CR8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","volume":"313","author":"M Tuchman","year":"1985","unstructured":"Tuchman M, Stoeckeler JS, Kiang DT, O\u2019Dea RF, Ramnaraine ML, Mirkin BL (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245\u2013249","journal-title":"N Engl J Med"},{"key":"2309_CR9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tips.2007.09.009","volume":"28","author":"C Mercier","year":"2007","unstructured":"Mercier C, Ciccolini J (2007) Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 28:597\u2013598","journal-title":"Trends Pharmacol Sci"},{"key":"2309_CR10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","volume":"81","author":"RB Diasio","year":"1988","unstructured":"Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47\u201351","journal-title":"J Clin Invest"},{"key":"2309_CR11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","volume":"68","author":"BE Harris","year":"1991","unstructured":"Harris BE, Carpenter JT, Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68:499\u2013501","journal-title":"Cancer"},{"key":"2309_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dna.1995.14.1","volume":"14","author":"R Meinsma","year":"1995","unstructured":"Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ (1995) Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 14:1\u20136","journal-title":"DNA Cell Biol"},{"key":"2309_CR13","first-page":"5433","volume":"53","author":"Z Lu","year":"1993","unstructured":"Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433\u20135438","journal-title":"Cancer Res"},{"key":"2309_CR14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0009-9236(95)90171-X","volume":"58","author":"Z Lu","year":"1995","unstructured":"Lu Z, Zhang R, Diasio RB (1995) Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 58:512\u2013522","journal-title":"Clin Pharmacol Ther"},{"key":"2309_CR15","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Ren\u00e9e N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248\u20132253","journal-title":"J Clin Oncol"},{"key":"2309_CR16","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"AB Kuilenburg van","year":"2004","unstructured":"van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939\u2013950","journal-title":"Eur J Cancer"},{"key":"2309_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/geno.1998.5379","volume":"51","author":"X Wei","year":"1998","unstructured":"Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, Gonzalez FJ (1998) Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51:391\u2013400","journal-title":"Genomics"},{"key":"2309_CR18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CCC.2010.n.033","volume":"9","author":"J Ciccolini","year":"2010","unstructured":"Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C (2010) Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 9:224\u2013228","journal-title":"Clin Colorectal Cancer"},{"key":"2309_CR19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","volume":"10","author":"ES Collie-Duguid","year":"2000","unstructured":"Collie-Duguid ES, Etienne MC, Milano G, McLeod HL (2000) Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10:217\u2013223","journal-title":"Pharmacogenetics"},{"key":"2309_CR20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/pgs.11.72","volume":"12","author":"U Amstutz","year":"2011","unstructured":"Amstutz U, Froehlich TK, Largiad\u00e8r CR (2011) Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12:1321\u20131336","journal-title":"Pharmacogenomics"},{"key":"2309_CR21","first-page":"2899","volume":"52","author":"RA Fleming","year":"1992","unstructured":"Fleming RA, Milano G, Thyss A, Etienne MC, Ren\u00e9e N, Schneider M, Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899\u20132902","journal-title":"Cancer Res"},{"key":"2309_CR22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","volume":"79","author":"G Milano","year":"1999","unstructured":"Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Ren\u00e9e N (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627\u2013630","journal-title":"Br J Cancer"},{"key":"2309_CR23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","volume":"101","author":"AB Kuilenburg van","year":"2002","unstructured":"van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14\u00a0+\u00a01\u00a0g\u00a0>\u00a0a mutation. Int J Cancer 101:253\u2013258","journal-title":"Int J Cancer"},{"key":"2309_CR24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","volume":"17","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M, Gu\u00e9rin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17:1105","journal-title":"J Clin Oncol"},{"key":"2309_CR25","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1177\/147323001003800413","volume":"38","author":"MH Kristensen","year":"2010","unstructured":"Kristensen MH, Pedersen P, Mejer J (2010) The value of dihydrouracil\/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 38:1313\u20131323","journal-title":"J Int Med Res"},{"key":"2309_CR26","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00280-011-1661-5","volume":"68","author":"MC Staveren van","year":"2011","unstructured":"van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, van Kuilenburg ABP, Maring JG (2011) Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol 68:1611\u20131617","journal-title":"Cancer Chemother Pharmacol"},{"key":"2309_CR27","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","volume":"10","author":"LK Mattison","year":"2004","unstructured":"Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10:2652\u20132658","journal-title":"Clin Cancer Res"},{"key":"2309_CR28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB (2006) The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res 12:549\u2013555","journal-title":"Clin Cancer Res"},{"key":"2309_CR29","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197\u2013201","journal-title":"Cancer Res"},{"key":"2309_CR30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/FTD.0b013e318240405f","volume":"34","author":"IC Cesar","year":"2012","unstructured":"Cesar IC, Cunha-J\u00fanior GF, Duarte Byrro RM, Coelho LG, Pianetti GA (2012) A rapid HPLC-ESI-MS\/MS method for determination of Dihydrouracil\/Uracil ratio in plasma: evaluation of toxicity to 5-Flurouracil in patients with gastrointestinal cancer. Therapeutic Drug Monit 34:59\u201366","journal-title":"Therapeutic Drug Monit"},{"key":"2309_CR31","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1093\/nar\/19.19.5444","volume":"19","author":"DK Lahiri","year":"1991","unstructured":"Lahiri DK, Nurnberger JI Jr (1991) A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444","journal-title":"Nucleic Acids Res"},{"key":"2309_CR32","unstructured":"Wagner Analysen Technik GmbH. http:\/\/www.wagner-bremen.de . Last assessed in Aug 15th, 2011"},{"key":"2309_CR33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0261-5614(95)80012-3","volume":"14","author":"S Amarri","year":"1995","unstructured":"Amarri S, Weaver LT (1995) 13C-breath tests to measure fat and carbohydrate digestion in clinical practice. Clin Nutr 14:149\u2013154","journal-title":"Clin Nutr"},{"key":"2309_CR34","doi-asserted-by":"crossref","first-page":"047002","DOI":"10.1088\/1752-7155\/3\/4\/047002","volume":"3","author":"HH Ezzeldin","year":"2009","unstructured":"Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB (2009) (13) C-5-FU breath test current status and future directions: a comprehensive review. J Breath Res 3:047002","journal-title":"J Breath Res"},{"key":"2309_CR35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2307\/2987937","volume":"32","author":"DG Altman","year":"1983","unstructured":"Altman DG, Bland JM (1983) Measurement in medicine: the analysis of method comparison studies. Statistician 32:307\u2013317","journal-title":"Statistician"},{"key":"2309_CR36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/bj3640157","volume":"364","author":"AB Kuilenburg van","year":"2002","unstructured":"van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ, Maropoulos GD, Hein G, Kalhoff H, Kirk JM, Baaske H, Aukett A, Duley JA, Ward KP, Lindqvist Y, van Gennip AH (2002) Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 364:157\u2013163","journal-title":"Biochem J"},{"key":"2309_CR37","doi-asserted-by":"crossref","first-page":"e4003","DOI":"10.1371\/journal.pone.0004003","volume":"3","author":"E Gross","year":"2008","unstructured":"Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, Kiechle M, Lordick F, Meindl A (2008) Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS ONE 3:e4003","journal-title":"PLoS ONE"},{"issue":"4","key":"2309_CR38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-006-0392-5","volume":"60","author":"MW Saif","year":"2007","unstructured":"Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB (2007) DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 60(4):503\u2013507","journal-title":"Cancer Chemother Pharmacol"},{"key":"2309_CR39","unstructured":"International Agency for Research on Cancer (IARC) (2011) Colorectal Cancer Incidence and Mortality Worldwide in 2008: Summary. http:\/\/globocan.iarc.fr\/factsheets\/cancers\/colorectal.asp . Last assessed in August 15th, 2011"},{"key":"2309_CR40","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00280-008-0889-1","volume":"63","author":"C Mercier","year":"2009","unstructured":"Mercier C, Dupuis C, Blesius A, Fanciullino R, Yang CG, Padovani L, Giacometti S, Frances N, Iliadis A, DuVaud F, Ciccolini J (2009) Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother Pharmacol 63:1177\u20131180","journal-title":"Cancer Chemother Pharmacol"},{"key":"2309_CR41","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","volume":"26","author":"M Schwab","year":"2008","unstructured":"Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26:2131\u20132138","journal-title":"J Clin Oncol"},{"key":"2309_CR42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/FPC.0b013e3282f01788","volume":"17","author":"HR Thomas","year":"2007","unstructured":"Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB (2007) Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 17:973\u2013987","journal-title":"Pharmacogenet Genomics"},{"key":"2309_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FPC.0b013e3282f2f134","volume":"18","author":"HR Thomas","year":"2008","unstructured":"Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB (2008) Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 18:25\u201335","journal-title":"Pharmacogenet Genomics"},{"key":"2309_CR44","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1002\/1097-0142(19931215)72:12<3715::AID-CNCR2820721225>3.0.CO;2-W","volume":"72","author":"LE Davis","year":"1993","unstructured":"Davis LE, Lenkinski RE, Shinkwin MA, Kressel HY, Dal JM (1993) The Effect of Dietary Protein Depletion on Hepatic 5-Fluorouracil Metabolism. Cancer 72:3715\u20133722","journal-title":"Cancer"},{"key":"2309_CR45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3177\/jnsv.37.517","volume":"37","author":"M Kaneko","year":"1991","unstructured":"Kaneko M, Fujimoto S, Kikugawa M, Kontani Y, Tamaki N (1991) Effect of dietary protein on pyrimidine-metabolizing enzymes in rats. J Nutr Sci Vitaminol 37:517\u2013528","journal-title":"J Nutr Sci Vitaminol"},{"issue":"3","key":"2309_CR46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00280-011-1666-0","volume":"68","author":"PY Cordier","year":"2011","unstructured":"Cordier PY, Nau A, Ciccolini J, Oliver M, Mercier C, Lacarelle B (2011) Peytel E5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. Cancer Chemother Pharmacol 68(3):823\u2013826","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2309-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2309-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2309-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T17:13:46Z","timestamp":1564420426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2309-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,8]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2309"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2309-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,8]]}}}